This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Harnessing the power of antibodies to fight bone metastasis
- Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer
- Tumor Dosimetry and Response for 153Sm-Ethylenediamine Tetramethylene Phosphonic Acid Therapy of High-Risk Osteosarcoma
- Comparison of Systemic Toxicities of 177Lu-DOTMP and 153Sm-EDTMP Administered Intravenously at Equivalent Skeletal Doses to Normal Dogs
- Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma
- Intraorgan Biodistribution and Dosimetry of 153Sm-Ethylenediaminetetramethylene Phosphonate in Juvenile Rabbit Tibia: Implications for Targeted Radiotherapy of Osteosarcoma
- Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma
- Effects of 153Sm-Ethylenediaminetetramethylene Phosphonate on Physeal and Articular Cartilage in Juvenile Rabbits
- Bone Uptake Studies in Rabbits Before and After High-Dose Treatment with 153Sm-EDTMP or 186Re-HEDP
- High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation
- High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases
- High-Dose Treatment with 186Re-HEDP or 153Sm-EDTMP Combined with Amifostine in a Rabbit Model
- Therapy of Metastatic Bone Pain
- Skeletal Uptake and Soft-Tissue Retention of 186Re-HEDP and 153Sm-EDTMP in Patients with Metastatic Bone Disease
- Current Concepts Review - Treatment of Metastatic Adenocarcinoma of the Pelvis and the Extremities